Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Phase II Study on Recombinant Botulinum Toxin Type a (YY001) for Injection in the Treatment of Upper Limb Spasticity in Adults
- Conditions
- Upper Limb Spasticity
- Interventions
- Biological: Recombinant Botulinum Toxin Type A for injection (YY001)Biological: Placebo
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06783114
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The Second People's Hospital of Hefei, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 488
- Registration Number
- NCT06583486
- Locations
- 🇨🇳
Guangdong Second People's Hospital, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 529
- Registration Number
- NCT06499688
- Locations
- 🇨🇳
Guangdong Second People's Hospital, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- Interventions
- Biological: Vehicle Control
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT06481475
- Locations
- 🇦🇺
St George Dermatology & Skin Cancer Centre, Sydney, New South Wales, Australia
🇦🇺Skin Health Institute, Melbourne, Victoria, Australia
🇦🇺Dermatology Institute of Victoria, Melbourne, Victoria, Australia
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT05743634
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳The First affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, China